Navitoclax和Vesimune在原位膀胱癌小鼠模型中的聯合治療作用
王宗偉1、謝政哲2,3,4、林志學5
台中榮民總醫院埔里分院 外科部 泌尿科1
國立中興大學生物醫學所2 台中榮民總醫院教學研究部3
國立中興大學轉譯醫學中心4 弘光科技大學 醫療健康學院 營養系5
The combinative effect of Navitoclax and Vesimune for bladder cancer in an orthotopic bladder cancer murine model
Tsung-Wei Wang MD 1, Jeng-Jer Shieh PhD2,3,4, Chih-Hsueh Lin PhD5
Division of Urology, Departments of Surgery, Puli Branch, Taichung Veterans General Hospital 1
Institute of Biomedical Sciences, National Chung Hsing University2
Department of Education and Research, Taichung Veterans General Hospital3
Rong Hsing Research Center for Translational Medicine, National Chung Hsing University4
Department of Nutrition, College of Medical and health care, Hung Kuang University 5
Purpose: Navitoclax, an experimental anti-Bcl-2 oral-active experimental drug, had been suggested for combinative strategy in bladder cancer therapy. Vesimune, formulations of toll-like receptor 7 agonist, was a safe and well tolerated drug for non-muscle invasive bladder cancer. Our goal was to evaluate the efficacy of the combinative efficacy of Navitoclax and Vesimune in an orthotopic murine model.
Materials and Methods: Five groups, including control, M group, MA group, MI group, MIA group, of 25 murine received an instillation with MBT-2 tumor cells on day 0, starting tumor development. M group is without drug treatment. MA group is treated with Navitoclax, MI group with Vesimune and MIA with both Navitoclax and Vesimune. The treatment strategy follows as: On day 14, 21 and 28, the murine were treated with an intravesical instillation of Vesimune 0.2mg/0.1ml. Navitoclax 50 mg/kg, PO, QOD for treatment between the day14 to day 28. On day 29 the murine were sacrificed and the bladders were evaluated histopathologically.
Results: The histopathological form reveals a tendency between positive control and experimental groups, which is decreased epithelial aggregation between M and MI/MIA group. No muscular invasion was noted in MI and MIA group.
Conclusion: In this murine bladder cancer model, Treatment with intravesical Vesimune instillation resulted in less tumor-bearing murine compared to Navitoclax or control groups. The combinative treatment of Navitoclax and Vesimune reveals a trend for synergistic antitumor effect.